Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review

Lung cancer is one of the most common malignant tumors and it is the leading cause of cancer-related mortality worldwide. For early-stage Non-Small Cell Lung Cancer (NSCLC), surgical resection is the treatment of choice, but the 5-year survival is still unsatisfying, ranging from 60% to 36% dependin...

Full description

Bibliographic Details
Main Authors: Lavinia Gatteschi, Mauro Iannopollo, Alessandro Gonfiotti
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Life
Subjects:
resectable NSCLC
neoadjuvant immunotherapy
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2075-1729/11/10/1036

Internet

https://www.mdpi.com/2075-1729/11/10/1036

Similar Items